Horizon acquires Hyperion for $960mm
Executive Summary
Horizon Pharma PLC acquired public US biotech Hyperion Therapeutics Inc. (orphan drug candidates for urea cycle disorders (UCDs) and hepatic encephalopathy (HE)) for $960mm, paying $46 apiece (a 13% premium) in cash for all Hyperion’s outstanding shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice